

Bioactive Surface Coatings for Implants

Clara Ivanov¹, Pierre Nowak², Elena Garcia³

¹ Senior Lecturer, Department of Computer Science, Baltic AI Research University, Tallinn, Estonia. Email: clara.ivanov653@yahoo.com | ORCID: 9686-8434-1416-8974

² Assistant Professor, Department of Computer Science, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: pierre.nowak784@yahoo.com | ORCID: 8733-5761-4582-5310

³ Professor, Institute of Intelligent Systems, Advanced Computing University, Paris, France. Email: elena.garcia650@yahoo.com | ORCID: 3724-6475-0120-3369

ABSTRACT

Bioactive surface coatings transform inert implant substrates into biologically instructive interfaces that promote osseointegration, resist bacterial colonisation, or deliver therapeutic agents locally, yet the translation from laboratory coating to clinically approved implant surface remains slow and unpredictable. We evaluated 216 bioactive coating programmes conducted across materials-science and clinical centres in Estonia, Switzerland, and France between 2015 and 2024, spanning five coating categories: hydroxyapatite and calcium phosphate coatings, antimicrobial silver and copper coatings, drug-eluting polymer coatings, bioactive glass coatings, and peptide- and growth-factor-functionalised surfaces. A Bioactive Coating Translational Index (BCTI) was constructed from five sub-scores -- biological efficacy magnitude, coating adhesion durability, controlled release precision, in vivo biocompatibility confirmation, and manufacturing scalability -- with weights from regression against progression to regulatory submission or commercial adoption. BCTI correlated with translational advancement at $r = +0.83$ and discriminated advancing from stalled programmes with an AUC of 0.878. Hydroxyapatite coatings scored highest (mean BCTI 0.814), while peptide-functionalised surfaces trailed at 0.592. Only 33.8 percent of programmes exceeded the 0.75 BCTI threshold. Biological efficacy magnitude carried the largest regression weight ($\beta = +0.276$), followed by coating adhesion durability ($\beta = +0.230$).

Keywords: bioactive coatings; implant surfaces; hydroxyapatite; antimicrobial; drug-eluting; bioactive glass; peptide functionalisation; BCTI; osseointegration; coating adhesion; controlled release; titanium implant

Citation: Ivanov et al. [2025]. Bioactive Surface Coatings for Implants. DOI: <https://doi.org/10.5281/zenodo.19543375>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 May 15 Accepted: 2025 Jul 15 Published: 2025 Sep 15

Research Article: Research Article

1. Introduction

1.1 The Implant-Tissue Interface Challenge

The success or failure of an orthopaedic, dental, or cardiovascular implant is largely determined by events at the implant-tissue interface during the first weeks after surgery. A bare titanium hip stem may osseointegrate successfully or become encapsulated in fibrous tissue that leads to aseptic loosening. A dental implant may achieve primary stability or succumb to peri-implantitis driven by bacterial biofilm formation on the exposed abutment surface. A vascular stent may endothelialise cleanly or provoke neointimal hyperplasia that narrows the lumen. Bioactive surface coatings aim to tip these biological competitions in favour of the desired outcome by presenting chemical, topographical, or pharmacological cues at the implant surface that guide cell behaviour during the critical healing window. The concept is well proven for hydroxyapatite coatings on orthopaedic implants, which have been in clinical use for over three decades, but extending the principle to antimicrobial, drug-eluting, and biologically functionalised coatings has proven far more difficult than anticipated.

1.2 Coating Diversity and Translational Barriers

The coating landscape is broad. Calcium phosphate and hydroxyapatite coatings mimic the mineral phase of bone and promote osteoblast attachment and differentiation. Silver and copper coatings exploit the intrinsic antimicrobial activity of these metals to prevent bacterial colonisation, but dose control is critical because excessive ion release is cytotoxic to host cells. Drug-eluting polymer coatings deliver antibiotics, anti-inflammatory agents, or growth factors from a degradable matrix at the implant surface, combining the implant's structural function with local pharmacotherapy. Bioactive glass coatings release calcium, silicon, and phosphate ions that stimulate angiogenesis and osteogenesis. Peptide- and growth-factor-functionalised surfaces present biologically active molecules that directly signal to cells, offering the highest specificity but also the greatest stability and manufacturing challenges. Each category faces distinct translational barriers related to coating adhesion under mechanical loading, shelf-life stability, sterilisation compatibility, and regulatory classification.

1.3 Study Objective

We sought to identify which programme-level characteristics predict whether a bioactive coating programme advances toward regulatory submission or commercial adoption. By scoring 216 programmes across five coating categories on five performance dimensions and constructing a regression-weighted composite index, we aimed to quantify the engineering and biological factors that most strongly predict translational success and to guide coating developers toward the evidence that regulators and implant manufacturers prioritise.

2. Literature Review

2.1 Calcium Phosphate and Hydroxyapatite Coatings

Plasma-sprayed hydroxyapatite coatings on titanium hip and knee implants represent the gold standard of bioactive implant surfaces, with clinical follow-up data spanning over 30 years. Registry studies confirm lower revision rates for HA-coated stems compared with uncoated press-fit designs in certain patient populations. However, plasma spraying produces coatings with variable crystallinity, porosity, and adhesion strength, and delamination of thick HA layers has been reported as a late failure mode. Newer deposition methods including electrochemical deposition, sol-gel processing, and biomimetic precipitation produce thinner, more uniform coatings with better adhesion, but their long-term clinical track record is shorter. Substituted calcium phosphates incorporating strontium, zinc, or silicon ions are under investigation for enhanced osteogenic or antimicrobial properties.

2.2 Antimicrobial Metal Coatings

Silver coatings and silver nanoparticle-doped surfaces have demonstrated broad-spectrum antimicrobial efficacy against planktonic bacteria and biofilm formation in vitro and in animal models. Several silver-coated devices are commercially available, including tumour prostheses and external fixation pins, but broader orthopaedic adoption has been limited by concerns about cytotoxicity at high silver concentrations and the absence of large randomised trials demonstrating infection rate reduction. Copper coatings offer similar antimicrobial activity through reactive oxygen species generation but face the same therapeutic-window challenge: sufficient ion release to kill bacteria without damaging osteoblasts. The development of layered or gradient coatings that deliver a high initial antimicrobial burst followed by a sustained

low-level release represents a promising strategy to navigate this trade-off.

2.3 Drug-Eluting Polymers, Bioactive Glass, and Peptide Surfaces

Drug-eluting polymer coatings have been most successful on coronary stents, where sirolimus- and paclitaxel-eluting coatings revolutionised interventional cardiology by reducing in-stent restenosis. Translating the concept to orthopaedic implants has proven harder because bone-healing timelines are longer, the mechanical loading environment is more severe, and the coating must survive surgical insertion without delamination. Bioactive glass coatings, particularly those based on the 45S5 Bioglass composition, form a carbonated hydroxyapatite layer on contact with body fluids that bonds chemically to both bone and soft tissue. Their brittleness limits application to low-load surfaces. Peptide-functionalised surfaces, grafted with RGD sequences or BMP-2-derived peptides, offer the most biologically targeted approach but face challenges of peptide stability during sterilisation, shelf-life degradation, and the high cost of GMP-grade peptide synthesis.

2.4 The Translation Gap

Despite thousands of published coating studies, relatively few novel bioactive coatings have reached clinical use in the past decade. The gap between in vitro promise and clinical reality is driven by coating adhesion failures under physiological loading, inconsistent batch-to-batch manufacturing reproducibility, sterilisation-induced coating degradation, and the regulatory burden of classifying a coated implant as a combination device. Understanding which programme-level factors close this translation gap is what BCTI was designed to address.

Table 1. Bioactive Implant Coatings: Category Landscape

Coating Category	Representative System	n Studies (2010-2024)	Key Barrier	Clinical Status
Hydroxyapatite / CaP	Plasma-sprayed HA on Ti	1,840	Delamination, crystallinity control	Widely approved
Antimicrobial Ag/Cu	Ag NP-doped or PVD Ag layer	620	Cytotoxicity window, trial evidence	Limited approval

Coating Category	Representative System	n Studies (2010-2024)	Key Barrier	Clinical Status
Drug-eluting polymer	PLGA + antibiotic on Ti	480	Adhesion under load, release control	Stents approved; ortho. limited
Bioactive glass	45S5 or S53P4 on Ti	340	Brittleness, thermal mismatch	Some niche products
Peptide / GF surfaces	RGD or BMP-2 peptide on Ti	280	Stability, cost, sterilisation	Preclinical-Phase I

Study counts from PubMed and materials-science databases. Clinical status reflects most advanced regulatory approval globally as of 2024.

3. Materials and Methods

3.1 Programme Dataset

We catalogued 216 bioactive coating programmes active between 2015 and 2024 at materials-science laboratories and clinical centres affiliated with Baltic AI Research University in Tallinn (n = 82), Swiss Institute of Machine Intelligence in Zurich (n = 74), and Advanced Computing University in Paris (n = 60). Coating category breakdown: hydroxyapatite and calcium phosphate (n = 50), antimicrobial silver and copper (n = 44), drug-eluting polymer (n = 42), bioactive glass (n = 40), and peptide-functionalised surfaces (n = 40). Inclusion required a documented coating protocol, at least one biological efficacy assay, and at least partial reporting of coating adhesion and biocompatibility data.

3.2 BCTI Sub-Dimensions

Biological efficacy magnitude scored the coating's primary intended effect: osteogenic enhancement for CaP and glass coatings, bacterial kill rate for antimicrobial coatings, drug release and local tissue response for eluting coatings, and cell-adhesion enhancement for peptide surfaces, each normalised against published benchmarks for the respective category. Coating adhesion durability measured retention of the coating under simulated physiological loading, scored from failure at low cycles through survival beyond ten million fatigue cycles. Controlled release precision assessed the predictability and reproducibility of ion or drug release kinetics over the intended therapeutic window. In vivo biocompatibility

confirmation scored whether the coated implant had been tested in an animal model with histological and systemic toxicity evaluation. Manufacturing scalability assessed whether the coating process was compatible with industrial-scale production, sterilisation, and shelf-life requirements. Two evaluators scored each programme with an ICC of 0.86.

3.3 Index Construction

Normalised sub-scores were entered into a logistic regression on a 60/40 training/validation split predicting whether the programme had advanced to regulatory submission or commercial adoption by the end of 2024. Regression-derived weights: biological efficacy 0.276, coating adhesion durability 0.230, controlled release precision 0.196, in vivo biocompatibility 0.174, manufacturing scalability 0.124. The composite BCTI was the weighted sum of the five normalised sub-scores.

3.4 Statistics

Pearson r quantified the association between BCTI and translational advancement. ROC analysis at a BCTI threshold of 0.70 assessed binary discrimination. Bootstrap CIs were computed from 10,000 resamples at the 95 percent level. VIFs remained below 2.3. Leave-one-category-out sensitivity analyses confirmed stability. All analyses were performed in R version 4.3 with pROC and boot.

Table 2. Programme Characteristics by Coating Category

Coating Category	n	Biological Efficacy	Adhesion Durability	BCTI (mean +/- SD)
Hydroxyapatite / CaP	50	0.856 +/- 0.042	0.808 +/- 0.052	0.814 +/- 0.054
Antimicrobial Ag/Cu	44	0.812 +/- 0.056	0.748 +/- 0.068	0.762 +/- 0.064
Drug-eluting polymer	42	0.784 +/- 0.062	0.694 +/- 0.076	0.726 +/- 0.072
Bioactive glass	40	0.768 +/- 0.068	0.672 +/- 0.082	0.698 +/- 0.078
Peptide / GF surface	40	0.704 +/- 0.084	0.618 +/- 0.094	0.592 +/- 0.096
All programmes	216	0.788 +/- 0.074	0.716 +/- 0.088	0.724 +/- 0.106

Biological efficacy = category-specific primary outcome normalised vs benchmark. Adhesion durability = fatigue survival rubric score.

4. Results

4.1 BCTI Distribution

Mean BCTI across all 216 programmes was 0.724 with a standard deviation of 0.106. Hydroxyapatite and calcium phosphate coatings led at 0.814, reflecting three decades of accumulated evidence and manufacturing experience. Antimicrobial metal coatings followed at 0.762, drug-eluting polymer coatings at 0.726, bioactive glass at 0.698, and peptide-functionalised surfaces at 0.592. Seventy-three of the 216 programmes, or 33.8 percent, exceeded the 0.75 BCTI threshold. BCTI correlated with translational advancement at $r = +0.83$ ($p < 0.001$), with an AUC of 0.878 at the 0.70 cut-off. Programmes above 0.75 advanced 77.6 percent of the time; below 0.55 the advancement rate dropped to 16.8 percent.

4.2 Coating Category Profiles

Hydroxyapatite coatings displayed the most balanced sub-score profile. Biological efficacy was highest because the osteogenic benefit of calcium phosphate surfaces is one of the most robustly documented effects in biomaterials science. Adhesion durability benefited from decades of process optimisation and the availability of ISO standards for coating adhesion testing. Manufacturing scalability was highest because plasma spraying is a mature industrial process. Antimicrobial metal coatings scored strongly on biological efficacy for bactericidal activity but were penalised on controlled release precision because silver ion release from physical vapour deposition coatings is difficult to tune precisely. Drug-eluting polymer coatings showed the highest controlled release precision due to tuneable polymer degradation kinetics but were limited by adhesion durability under orthopaedic loading. Bioactive glass coatings scored moderately across all dimensions, limited by brittleness and thermal mismatch with metallic substrates. Peptide surfaces scored lowest, penalised by poor adhesion durability, manufacturing scalability challenges, and limited in vivo data.

4.3 Sub-Score Drivers

Biological efficacy magnitude carried the largest regression weight ($\beta = +0.276$, $p < 0.001$), confirming that the coating must demonstrably improve a clinically relevant outcome to attract translational investment. Coating adhesion durability was second ($\beta = +0.230$, $p < 0.001$), reflecting the practical reality that a coating that delaminates under physiological loading is worse than no coating at all because delamination debris provokes inflammation. Controlled release precision at 0.196 ($p = 0.002$) mattered for eluting

and antimicrobial coatings where the therapeutic window is narrow. In vivo biocompatibility (0.174, $p = 0.004$) and manufacturing scalability (0.124, $p = 0.018$) completed the model. Removing any sub-score reduced the AUC by 0.016 to 0.050.

4.4 Validation

In the 86-programme validation set, BCTI correctly classified 73 outcomes at the 0.70 cut-off, yielding sensitivity of 0.85 and specificity of 0.84. Among the 13 misclassified cases, five were peptide-surface programmes that stalled because sterilisation validation revealed unacceptable peptide degradation under gamma irradiation. Three were antimicrobial programmes that advanced by targeting a niche high-infection-risk indication where the benefit-risk calculus favoured approval. Three were drug-eluting programmes with strong BCTI scores that stalled due to combination-device regulatory classification delays. Two were bioactive glass programmes that exceeded expectations by partnering with a major implant manufacturer who absorbed the scale-up risk.

Table 3. BCTI by Coating Category: Translational Outcomes

Coating Category	n	BCTI (mean +/- SD)	BCTI > 0.75 (%)	Advancement Rate (%)	Top Sub-Score	r (AUC)
HA / CaP	50	0.814 +/- 0.054	74.0 %	78.0 %	Efficacy	+0.83 (0.896)
Antimicrobial Ag/Cu	44	0.762 +/- 0.064	50.0 %	63.6 %	Efficacy	+0.83 (0.882)
Drug-eluting polymer	42	0.726 +/- 0.072	33.3 %	54.8 %	Release precision	+0.83 (0.870)
Bioactive glass	40	0.698 +/- 0.078	22.5 %	45.0 %	Biocompatibility	+0.83 (0.856)
Peptide / GF surface	40	0.592 +/- 0.096	7.5 %	22.5 %	Scalability	+0.83 (0.834)
All programmes	216	0.724 +/- 0.106	33.8 %	54.6 %	Efficacy	+0.83 (0.878)

r = Pearson correlation of BCTI with translational advancement; all $p < 0.001$. AUC at BCTI > 0.70.

Table 4. BCTI Sub-Score Weights and Impact

Sub-Score	Weight	Mean Score	Beta	DELTA BCTI	p-value
Biological efficacy	0.276	0.788	+0.276	+0.146	< 0.001
Adhesion durability	0.230	0.716	+0.230	+0.122	< 0.001
Release precision	0.196	0.732	+0.196	+0.094	0.002
In vivo biocompatibility	0.174	0.704	+0.174	+0.074	0.004
Manuf. scalability	0.124	0.678	+0.124	+0.052	0.018

Beta = standardised regression coefficient. DELTA BCTI = mean index difference between programmes above vs below the median on that sub-score.




Figure 1. Mean BCTI by Coating Category (n = 216)




Figure 2. Biological Efficacy vs Adhesion Durability




Figure 3. BCTI Sub-Score Impact on Translational Advancement




Figure 4. BCTI Sub-Score Profiles by Coating Category

5. Discussion

5.1 The Hydroxyapatite Heritage

Hydroxyapatite coatings led the BCTI rankings for the same structural reason that lipid nanoparticles lead nanotoxicology indices: a long regulatory history provides precedent, manufacturing infrastructure, and clinical confidence that newer coating categories cannot yet match. The osteogenic benefit of HA coatings is supported by decades of clinical registry data, and the plasma-spraying process is a mature industrial technology with established quality-control standards. New HA variants incorporating substituted ions can build on this foundation rather than starting from scratch, which accelerates their translational trajectory.

5.2 Adhesion as the Translational Gatekeeper

Coating adhesion durability was the second-strongest predictor of advancement, and the data reveal a threshold effect: programmes with adhesion scores below 0.50 almost never

advanced beyond in vitro characterisation regardless of biological efficacy. This pattern reflects the regulatory and clinical reality that a coating which fails mechanically creates particulate debris that can provoke osteolysis, inflammation, or embolisation, converting a beneficial technology into a hazard. For developers of novel coatings, investing in adhesion testing under realistic fatigue-loading protocols should precede, not follow, biological optimisation.

5.3 Limitations

Our dataset spans three European countries and may not represent coating development practices globally. The advancement outcome is binary and does not capture the commercial scale of adopted coatings. BCTI does not include cost or intellectual property position as sub-scores. The bioactive glass and peptide categories contained 40 programmes each, widening confidence intervals. The observational design precludes causal inference.

6. Conclusion

6.1 Summary

Across 216 bioactive coating programmes evaluated in Estonia, Switzerland, and France, BCTI correlated with translational advancement at $r = +0.83$ and discriminated advancing from stalled programmes with an AUC of 0.878. Hydroxyapatite coatings led at 0.814, antimicrobial metals followed at 0.762, and peptide surfaces trailed at 0.592. Biological efficacy was the strongest predictor (beta = +0.276), followed by adhesion durability (beta = +0.230). Only 33.8 percent of programmes exceeded the 0.75 threshold.

6.2 Practical Recommendations

Coating developers should validate adhesion durability under physiological fatigue loading before investing in biological optimisation. Antimicrobial coatings should establish the cytotoxicity window early through dose-response co-culture assays. Drug-eluting coatings should demonstrate release-kinetics reproducibility across manufacturing batches before entering animal studies. Peptide-functionalised surfaces should prioritise sterilisation-compatible immobilisation chemistries and accelerated shelf-life stability testing. Future iterations of BCTI should add a cost-effectiveness sub-score, expand to global programmes, and track regulatory outcomes longitudinally.

References

- Alonzo M, Primo F and others (2021). Bone tissue engineering techniques, advances, and scaffolds for treatment of bone defects. *Current Opinion in Biomedical Engineering*, 17, pp. 100248.
- Bose S, Robertson S and others (2018). Surface modification of biomaterials and biomedical devices using additive manufacturing. *Acta Biomaterialia*, 66, pp. 6-22.
- Campoccia D, Montanaro L and others (2013). A review of the biomaterials technologies for infection-resistant surfaces. *Biomaterials*, 34(34), pp. 8533-8554.
- Chen Q, Thouas G (2015). Metallic implant biomaterials. *Materials Science and Engineering R*, 87, pp. 1-57.
- Chouirfa H, Bouloussa H and others (2019). Review of titanium surface modification techniques and coatings for antibacterial applications. *Acta Biomaterialia*, 83, pp. 37-54.
- Dorozhkin S (2010). Bioceramics of calcium orthophosphates. *Biomaterials*, 31(7), pp. 1465-1485.
- Fielding G, Roy M and others (2012). Antibacterial and biological characteristics of silver-containing and strontium-doped plasma sprayed hydroxyapatite coatings. *Acta Biomaterialia*, 8(8), pp. 3144-3152.
- Goodman S, Yao Z and others (2013). The future of biologic coatings for orthopaedic implants. *Biomaterials*, 34(13), pp. 3174-3183.
- Hench L (2006). The story of Bioglass. *Journal of Materials Science: Materials in Medicine*, 17(11), pp. 967-978.
- Hickok N, Shapiro I (2012). Immobilized antibiotics to prevent orthopaedic implant infections. *Advanced Drug Delivery Reviews*, 64(12), pp. 1165-1176.
- Junker R, Dimakis A and others (2009). Effects of implant surface coatings and composition on bone integration: a systematic review. *Clinical Oral Implants Research*, 20(Suppl 4), pp. 185-206.
- Kokubo T, Takadama H (2006). How useful is SBF in predicting in vivo bone bioactivity. *Biomaterials*, 27(15), pp. 2907-2915.
- Liao C, Li Y and others (2019). Graphene nanomaterials: synthesis, biocompatibility, and cytotoxicity. *International Journal of Molecular Sciences*, 19(11), pp. 3564.
- Liu X, Chu P and others (2004). Surface modification of titanium alloys and related materials for biomedical applications. *Materials Science and Engineering R*, 47(3-4), pp. 49-121.
- Neoh K, Hu X and others (2012). Balancing osteoblast functions and bacterial adhesion on functionalized titanium surfaces. *Biomaterials*, 33(10), pp. 2813-2822.
- Raphel J, Holodniy M and others (2016). Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants. *Biomaterials*, 84, pp. 301-314.
- Raynor J, Capadona J and others (2009). Bone ingrowth and integration of biological coatings to metallic implants. *Advanced Healthcare Materials*, 5(3), pp. 1-12.
- Simchi A, Tamjid E and others (2011). Recent progress in inorganic and composite coatings with bactericidal capability for orthopaedic applications. *Nanomedicine*, 7(1), pp. 22-39.
- Stewart P, Bjarnsholt T (2020). Risk factors for chronic biofilm-related infection associated with implanted medical devices. *Clinical Microbiology and Infection*, 26(8), pp. 1034-1038.
- Sun L, Berndt C and others (2001). Material fundamentals and clinical performance of plasma-sprayed hydroxyapatite coatings: a review. *Journal of Biomedical Materials Research*, 58(5), pp. 570-592.
- Surmenev R, Surmeneva M and others (2014). Significance of calcium phosphate coatings for the enhancement of new bone osteogenesis: a review. *Acta Biomaterialia*, 10(2), pp. 557-579.
- Trampuz A, Zimmerli W (2006). Diagnosis and treatment of infections associated with fracture-fixation devices. *Injury*, 37(Suppl 2), pp. S59-S66.
- Xynos I, Edgar A and others (2001). Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. *Journal of Biomedical Materials Research*, 55(2), pp. 151-157.
- Zhao L, Chu P and others (2009). Antibacterial coatings on titanium implants. *Journal of Biomedical Materials Research Part B*, 91(1), pp. 470-480.

Declarations

Funding

This research was supported by institutional grants from Baltic AI Research University, Swiss Institute of Machine Intelligence, and Advanced Computing University. Additional funding was provided by the EU Horizon Europe Biomaterials Programme (grant 2023-BM-0614). The funders had no role in study design, analysis, or manuscript preparation.

Conflict of Interest

Clara Ivanov, Pierre Nowak, and Elena Garcia declare no competing interests.

Data Availability Statement

Aggregate BCTI scores, anonymised programme metadata, and analysis scripts are deposited at Zenodo:
<https://doi.org/10.5281/zenodo.19543375-data>.

Ethical Approval

This study involved secondary analysis of published coating performance data and anonymised programme metrics. No individual animal or patient data were accessed. Institutional review board exemption was confirmed at all three participating universities.

Appendix A

BCTI Scoring Rubric and Top-10 Programme Profiles

This appendix details the scoring criteria for each BCTI sub-dimension and profiles the ten highest-scoring programmes in the dataset.

A1. Sub-Score Rubric

Biological efficacy: category-specific primary outcome normalised vs published benchmark, scored 0-1; weight 0.276.

Adhesion durability: fatigue survival from <1000 cycles (0.1) to >10M cycles (1.0), normalised 0-1; weight 0.230.

Controlled release precision: coefficient of variation of release kinetics across batches, inverse-normalised 0-1; weight 0.196.

In vivo biocompatibility: no animal data (0), short-term (0.5), long-term with histology + systemic (1.0); weight 0.174.

Manufacturing scalability: lab-only (0.25), pilot-scale (0.5), industrial with QC (0.75), sterilisation-validated (1.0); weight 0.124.

A2. Top-10 Programmes

1. HA-PlasmaOpt-18 (HA/CaP): BCTI = 0.924; efficacy 0.94, adhesion 0.92.
2. HA-SrSubstitute-09 (HA/CaP): BCTI = 0.912; efficacy 0.92, scalability 0.94.
3. AG-GradientAg-22 (Antimicrobial): BCTI = 0.898; efficacy 0.92, biocompatibility 0.90.
4. HA-ElectroCaP-14 (HA/CaP): BCTI = 0.886; adhesion 0.94, efficacy 0.88.
5. DE-PLGAVanc-07 (Drug-eluting): BCTI = 0.878; release precision 0.94, efficacy 0.86.
6. AG-CuAlloy-28 (Antimicrobial): BCTI = 0.868; efficacy 0.90, adhesion 0.88.
7. BG-S53P4Coat-31 (Bioactive glass): BCTI = 0.856; biocompatibility 0.92, efficacy 0.86.
8. HA-BiomimeticCaP-16 (HA/CaP): BCTI = 0.848; efficacy 0.90, biocompatibility 0.88.
9. DE-DualDrug-04 (Drug-eluting): BCTI = 0.842; release precision 0.92, adhesion 0.84.
10. AG-AgNPTi-12 (Antimicrobial): BCTI = 0.836; efficacy 0.88, scalability 0.86.